The rundown covers CagriSema, retatrutide, MariTide, VK2735 and Roche's enicepatide, which the company says cut weight by 15.5% on average in a mid-stage trial.
Recap by typeshit. Full story at qz.com.
PHL17 shares findings that people on Ozempic and similar drugs are cutting alcohol spending at bars, restaurants and home.
Omer Raheem says he presented his team's work on GLP-1 therapies past weight loss at the ISSM Journals Webinar 2026.
Zhavoronkov links recorded ARDD 2026 sessions, among them Lilly's Kevin Duffin speaking on tirzepatide and aging clocks.
Zhavoronkov quotes a speaker calling Mounjaro one of the best molecules humans have made, alongside Novo's semaglutide data at the aging conference.
A user says energy drops as their dose rises and eating protein gets harder, and asks others how they manage workouts and meals.
NewBeauty shares the New York dermatologist's view on filler candidates. The excerpt gives no clear link to peptides or GLP-1 drugs.
Loading…